Israeli scientists use placenta stem cells to treat COVID-19 patients and it works.
Israeli scientists have claimed that they can use a single placenta to cure as many as 20,000 coronavirus patients. The firm has already started treating the patients and is highly hopeful for positive outcomes as some patients have already shown significant improvement in symptoms.
The treatment shows 100% survival rate according to the preliminary data.
The medical breakthrough gave new hope to the long boredom and depression from lockdowns and home quarantine which caused chronic mental health problems in the past few months.
Pluristem Therapeutics started a multinational clinical trial of PLX cells for treating complications associated with COVID-19 while also helping severe patients recover from the disease under compassionate use programs in the US and Israel.
On April 11, physicians injected cells derived fromhealthy-birth placentas into the arm and leg muscles of a 49-year-old man who was critically ill. The patient has been in the ICU for nearly 3 weeks with his breathing supported by a ventilator. The hope is that the cells will modify his immune response and help heal damaged lung tissue.
Yaky Yanay, the company’s president and chief executive officer, said they are “pleased with the initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems.”
“In this time of emergency, we are honored to be taking part in the global effort to support patients and healthcare systems,” Pluristem president and CEO Yaky Yanay said.
“Pluristem is dedicated to using its competitive advantages in large-scale manufacturing to potentially deliver PLX cells to a large number of patients in significant need,” Yanay added.
Using the same technology, the company has treated seven Israelis and one American so far. The company’s shares have noticed a massive surge after the release of information about the potential of the placenta in the treatment of coronavirus infected patients.
Not only have all the patients survived, according to Pluristem, but four of them showed improvement in respiratory parameters and three of them are in the advanced stages of weaning from ventilators. Moreover, two of the patients with preexisting medical conditions are showing clinical recovery in addition to the respiratory improvement.
The US Food and Drug Administration (FDA) has already approved clinical trials to study covid-19 patients who have been administered MSC derived from the placenta to prevent inflammation of lungs.
Yanay said the company is in talks with regulators in Europe and the United States for the definition of their clinical strategy against the deadly disease.
Stem-cell therapy could help build up regenerative cells in the lungs, which could protect the epithelial cells of the lungs, prevent lung damage and help patients recover, according to some scientists.
Pluristem Therapeutics is a regenerative medicine company developing a platform of novel biological products. PLX, a placenta-based cell therapy, consists of off-the-shelf products that require no tissue matching prior to administration. Each patented PLX product releases a distinct combination of therapeutic proteins in response to signals from the patient’s body from tissues that have been damaged by conditions such as inflammation, ischemia, muscle injuries, hematological disorders, and exposure to radiation in order to stimulate the body’s own regenerative mechanisms.